Aragen's Solutions For Mitigating Challenges In Recombinant Protein Production

Recombinant proteins (RPs), produced through genetic engineering, encompass a wide variety of biologically important molecules — including antibodies, enzymes, and vaccines — that play a critical role in the biopharmaceutical industry. E. coli-based expression systems are commonly used for their speed, scalability, and cost-effectiveness in synthesizing these proteins. However, several inherent challenges — such as protein misfolding, inclusion body formation, or low expression levels — can hinder efficient production and reduce yields.

At Aragen, our skilled scientists deliver a streamlined, end-to-end protein expression and purification workflow designed to address these challenges head-on. Through the use of advanced mitigation strategies, we optimize yield, enhance protein quality, and ensure functional integrity, helping clients achieve efficient and reliable recombinant protein production using E. coli systems.